CoChat

Orotracheal treprostinil administration attenuates bleomycin‐induced lung injury, vascular remodeling, and fibrosis in mice

Open access

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Abstract

Pulmonary fibrosis is a progressive disease characterized by disruption of lung architecture and deregulation of the pulmonary function. Prostacyclin, a metabolite of arachidonic acid, is a potential disease mediator since it exerts anti‐inflammatory and anti‐fibrotic actions. We investigated the effect of treprostinil, a prostacyclin analogue, in bleomycin‐induced experimental pulmonary fibrosis. Bleomycin sulfate or saline was administrated intratracheally to mice ( n = 9–10/group) at day 0. Orotracheal aspiration of treprostinil or vehicle was administered daily and started 24 h prior to bleomycin challenge. Evaluation of lung pathology was performed in tissue samples and bronchoalveolar lavage fluid collected 7, 14 and 21 days after bleomycin exposure. Lung injury was achieved due to bleomycin exposure at all time points as indicated by impaired lung mechanics, pathologic lung architecture (from day 14), and cellular and protein accumulation in the alveolar space accompanied by a minor decrease in lung tissue VE‐cadherin at day 14. Treprostinil preserved lung mechanics, and reduced lung inflammation, fibrosis, and vascular remodeling (day 21); reduced cellularity and protein content of bronchoalveolar lavage fluid were additionally observed with no significant effect on VE‐cadherin expression. Bleomycin‐induced collagen deposition was attenuated by treprostinil from day 14, while treprostinil involvement in regulating inflammatory processes appears mediated by NF‐κB signaling. Overall, prophylactic administration of treprostinil, a stable prostacyclin analogue, maintained lung function, and prevented bleomycin‐induced lung injury, and fibrosis, as well as vascular remodeling, a hallmark of pulmonary hypertension. This suggests potential therapeutic efficacy of treprostinil in pulmonary fibrosis and possibly in pulmonary hypertension related to chronic lung diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2045894019881954

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Effect of orotracheal treprostinil (TREP) administration on lung mechanics of all animal groups 7, 14 and 21 days after intratracheal injection of bleomycin (BLM) or saline (SAL). BLM reduced lung static compliance (a–c) and increased tissue elastance (d–f), phenomena that were reversed in the BLM/TREP treated group. Results are expressed as mean ± SEM, n = 9–10 mice per group. One-way ANOVA followed by Newman–Keuls post hoc test was used for the comparison among groups. Cst: static compliance; H: tissue elastance coefficient; 7D: 7 days; 14D: 14 days; 21D: 21 days.
Fig. 1. Effect of orotracheal treprostinil (TREP) administration on lung mechanics of all animal groups 7, 14 and 21 days after intratracheal injection of bleomycin (BLM) or saline (SAL). BLM reduced lung static compliance (a–c) and increased tissue elastance (d–f), phenomena that were reversed in the BLM/TREP treated group. Results are expressed as mean ± SEM, n = 9–10 mice per group. One-way ANOVA followed by Newman–Keuls post hoc test was used for the comparison among groups. Cst: static compliance; H: tissue elastance coefficient; 7D: 7 days; 14D: 14 days; 21D: 21 days.CC BY-NC · PubMed Central
Fig. 2. Orotracheal treprostinil (TREP) administration attenuates bleomycin (BLM)-induced pulmonary inflammation and fibrosis. Following histological analysis of murine lungs included in each group at every time point, lung injury was quantified (a–c). Results are expressed as mean ± SEM, n = 9–10 mice per group. One-way ANOVA followed by Newman–Keuls post hoc test was used for comparison among groups. Representative H&E stainings are shown in (d–f); mice treated with bleomycin and treprostinil show less leukocyte accumulation, alveolar structure distortion and collagen deposition (d: 7D, e: 14D, f: 21D). SAL: saline; VEH: vehicle; 7D: 7 days; 14D: 14 days; 21D: 21 days.
Fig. 2. Orotracheal treprostinil (TREP) administration attenuates bleomycin (BLM)-induced pulmonary inflammation and fibrosis. Following histological analysis of murine lungs included in each group at every time point, lung injury was quantified (a–c). Results are expressed as mean ± SEM, n = 9–10 mice per group. One-way ANOVA followed by Newman–Keuls post hoc test was used for comparison among groups. Representative H&E stainings are shown in (d–f); mice treated with bleomycin and treprostinil show less leukocyte accumulation, alveolar structure distortion and collagen deposition (d: 7D, e: 14D, f: 21D). SAL: saline; VEH: vehicle; 7D: 7 days; 14D: 14 days; 21D: 21 days.CC BY-NC · PubMed Central
Fig. 3. Effect of treprostinil (TREP) treatment on inflammatory cell infiltration in bronchoalveolar lavage fluid (BALF) and on endothelial barrier disruption. Total cell counts (a–c) and neutrophil counts (d–f) in BALF collected at days 7, 14 and 21 post bleomycin (BLM). Collection of inflammatory cells in airways was significantly reduced in mice receiving BLM and treprostinil, compared to those receiving only BLM. Protein leakage in the airspace induced by BLM was reduced significantly at later stages, as shown by total protein concentrations (g–i). (j, k): Representative Western blot for VE-cadherin in mouse lung tissues 14 days post bleomycin and respective protein quantification after normalization with actin. Results are expressed as mean ± SEM, n = 9–10 mice per group. One-way ANOVA followed by Newman–Keuls post hoc test was used for comparison among groups. 7D: 7 days; 14D: 14 days; 21D: 21 days.
Fig. 3. Effect of treprostinil (TREP) treatment on inflammatory cell infiltration in bronchoalveolar lavage fluid (BALF) and on endothelial barrier disruption. Total cell counts (a–c) and neutrophil counts (d–f) in BALF collected at days 7, 14 and 21 post bleomycin (BLM). Collection of inflammatory cells in airways was significantly reduced in mice receiving BLM and treprostinil, compared to those receiving only BLM. Protein leakage in the airspace induced by BLM was reduced significantly at later stages, as shown by total protein concentrations (g–i). (j, k): Representative Western blot for VE-cadherin in mouse lung tissues 14 days post bleomycin and respective protein quantification after normalization with actin. Results are expressed as mean ± SEM, n = 9–10 mice per group. One-way ANOVA followed by Newman–Keuls post hoc test was used for comparison among groups. 7D: 7 days; 14D: 14 days; 21D: 21 days.CC BY-NC · PubMed Central
Fig. 4. Effect of treprostinil (TREP) treatment on pulmonary vascular remodeling in bleomycin (BLM)-challenged mice. Lung sections were stained for alpha (α)-smooth muscle actin, and pulmonary vascular remodeling was analyzed, in vessels of 20–70 µm diameter, 21 days post BLM. Representative images from all groups are shown (a–d): (a): animal treated with SAL and VEH, (b): animal treated with SAL and TREP, (c): animal treated with BLM and VEH, (d): animal treated with BLM and TREP. (e–g): Percentages of non-, partially and fully muscularized vessels are shown for each group. Data are presented as mean ± SEM (n = 4–7 mice per group). One-way ANOVA followed by Tukey’s multiple comparisons test was used for comparison among groups. SAL: saline; VEH: vehicle.
Fig. 4. Effect of treprostinil (TREP) treatment on pulmonary vascular remodeling in bleomycin (BLM)-challenged mice. Lung sections were stained for alpha (α)-smooth muscle actin, and pulmonary vascular remodeling was analyzed, in vessels of 20–70 µm diameter, 21 days post BLM. Representative images from all groups are shown (a–d): (a): animal treated with SAL and VEH, (b): animal treated with SAL and TREP, (c): animal treated with BLM and VEH, (d): animal treated with BLM and TREP. (e–g): Percentages of non-, partially and fully muscularized vessels are shown for each group. Data are presented as mean ± SEM (n = 4–7 mice per group). One-way ANOVA followed by Tukey’s multiple comparisons test was used for comparison among groups. SAL: saline; VEH: vehicle.CC BY-NC · PubMed Central
Fig. 5. Orotracheal administration of treprostinil (TREP) attenuates collagen deposition in bleomycin (BLM)-challenged mouse lungs. (a–c) Soluble collagen determination in lung extracts as measured by Sircol collagen kit 7, 14 and 21 days post BLM respectively. (g–i): Representative Masson staining of lung sections from samples collected at the aforementioned time points (g: 7D, h: 14D, i: 21D). Fibrotic injury in lung sections from all groups was given a score in order to be quantified and as shown in (d–f) the BLM/TREP group score was lower compared to BLM/VEH group. Results are expressed as mean ± SEM, n = 9–10 mice per group. One-way ANOVA followed by Newman–Keuls post hoc test was used for comparison among groups. SAL: saline; VEH: vehicle; 7D: 7 days; 14D: 14 days; 21D: 21 days.
Fig. 5. Orotracheal administration of treprostinil (TREP) attenuates collagen deposition in bleomycin (BLM)-challenged mouse lungs. (a–c) Soluble collagen determination in lung extracts as measured by Sircol collagen kit 7, 14 and 21 days post BLM respectively. (g–i): Representative Masson staining of lung sections from samples collected at the aforementioned time points (g: 7D, h: 14D, i: 21D). Fibrotic injury in lung sections from all groups was given a score in order to be quantified and as shown in (d–f) the BLM/TREP group score was lower compared to BLM/VEH group. Results are expressed as mean ± SEM, n = 9–10 mice per group. One-way ANOVA followed by Newman–Keuls post hoc test was used for comparison among groups. SAL: saline; VEH: vehicle; 7D: 7 days; 14D: 14 days; 21D: 21 days.CC BY-NC · PubMed Central
Fig. 6. Effect of treprostinil (TREP) on the production of osteopontin and periostin. Concentration of osteopontin (a–c) and periostin (d–f) was measured by ELISA in BALF collected 7, 14 and 21days post bleomycin (BLM). Results are expressed as mean ± SEM, n = 9–10 mice per group. One-way ANOVA followed by Newman–Keuls post hoc test was used for comparison among groups. SAL: saline; VEH: vehicle; 7D: 7 days; 14D: 14 days; 21D:21 days.
Fig. 6. Effect of treprostinil (TREP) on the production of osteopontin and periostin. Concentration of osteopontin (a–c) and periostin (d–f) was measured by ELISA in BALF collected 7, 14 and 21days post bleomycin (BLM). Results are expressed as mean ± SEM, n = 9–10 mice per group. One-way ANOVA followed by Newman–Keuls post hoc test was used for comparison among groups. SAL: saline; VEH: vehicle; 7D: 7 days; 14D: 14 days; 21D:21 days.CC BY-NC · PubMed Central
Fig. 7. Orotracheal administration of treprostinil (TREP) reduces phosphorylation of IκB and JNK. (a, c, e, g): Representative Western blots for p-ERK, p-p38, p-JNK and p-IκBα in mouse lung homogenates of samples collected 21 days post bleomycin (BLM)-challenge or vehicle (VEH). Total levels of MAPKs and actin were used as loading controls. (b, d, f, h): Quantification of protein levels after normalization is shown for each molecule. One-way ANOVA was used for comparison among groups and was followed by Tukey’s multiple comparisons test. Data are expressed as means ± SEM. Differences between BLM/VEH and SAL/VEH groups are shown by # (#p < 0.05); differences between BLM/VEH group and BLM/TREP group are shown by *. SAL: saline.
Fig. 7. Orotracheal administration of treprostinil (TREP) reduces phosphorylation of IκB and JNK. (a, c, e, g): Representative Western blots for p-ERK, p-p38, p-JNK and p-IκBα in mouse lung homogenates of samples collected 21 days post bleomycin (BLM)-challenge or vehicle (VEH). Total levels of MAPKs and actin were used as loading controls. (b, d, f, h): Quantification of protein levels after normalization is shown for each molecule. One-way ANOVA was used for comparison among groups and was followed by Tukey’s multiple comparisons test. Data are expressed as means ± SEM. Differences between BLM/VEH and SAL/VEH groups are shown by # (#p < 0.05); differences between BLM/VEH group and BLM/TREP group are shown by *. SAL: saline.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Research works printed but not linked: 2

  1. 10.1002/(sici)1097-4644(19981101)71:2<254::aid-jcb10>3.0.co;2-l · doi:10.1002/(sici)1097-4644(19981101)71:2<254::aid-jcb10>3.0.co;2-l
  2. Manitsopoulos N, 2015, Treprostinil administration attenuates bleomycin‐induced lung fibrosis in mice. [abstract], Eur Resp J, 46, PA3837

Cited by

See all 45

Metadata

Authors
Nikitopoulou, I., Manitsopoulos, N., Kotanidou, A., Tian, X., Petrovic, A., Magkou, C., Ninou, I., Aidinis, V., Schermuly, R. T., Kosanovic, D., & Orfanos, S. E.
Affiliations
  • National and Kapodistrian University of Athens (GR)
  • GP Livanos and M Simou Laboratories 1st Department of Critical Care &amp; Pulmonary Services Medical School National &amp; Kapodistrian University of Athens Evangelismos Hospital Athens Greece
  • Universities of Giessen and Marburg Lung Center Member of the German Center for Lung Research (DZL) Justus‐Liebig University Giessen Germany
  • Justus-Liebig-Universität Gießen (DE)
  • Department of Pathology Evangelismos Hospital Athens Greece
  • Alexander Fleming Biomedical Sciences Research Center (GR)
  • Sechenov University (RU)
Corresponding author
Orfanos, Stylianos E.
Venue
Pulmonary Circulation
Publisher
Wiley
Published
2019-10
Volume
9
Issue
4
Pages
1-14
ISSN
  • 2045-8932 (ISSN-L)
  • 2045-8940
OpenAlex
W2976822390
Cited by
44
References
62
Citations by year
2026: 4 · 2025: 8 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 5 · 2019: 1
FWCI
3.68
Type
journal article
Language
en
Open access
Licence
Locations
  • Pulmonary Circulation (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • United Therapeutics Corporation (TRE-NC-004)
  • Galenica-Ferrer (1348/2015)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords
treprostinil, prostacyclin analogues, pulmonary fibrosis, bleomycin-induced lung injury, vascular remodeling, pulmonary hypertension, NF-κB signaling, lung inflammation, collagen deposition, VE-cadherin, bronchoalveolar lavage fluid, lung mechanics, prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Orotracheal treprostinil administration attenuates bleomycin‐induced lung injury, vascular remodeling, and fibrosis in mice. https://app.cochat.ai/papers/10.1177/2045894019881954
The paper
Nikitopoulou, I., Manitsopoulos, N., Kotanidou, A., Tian, X., Petrovic, A., Magkou, C., Ninou, I., Aidinis, V., Schermuly, R. T., Kosanovic, D., & Orfanos, S. E. (2019). Orotracheal treprostinil administration attenuates bleomycin‐induced lung injury, vascular remodeling, and fibrosis in mice. Pulmonary Circulation. https://doi.org/10.1177/2045894019881954

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.